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Abstract Glucocorticosteroid-in-
duced osteoporosis (GIOP) is the
most frequent of all secondary types
of osteoporosis. The understanding
of the pathophysiology of glucocor-
ticoid (GC) induced bone loss is of
crucial importance for appropriate
treatment and prevention of debili-
tating fractures that occur predomi-
nantly in the spine. GIOP results
from depressed bone formation due
to lower activity and higher death
rate of osteoblasts on the one hand,
and from increased bone resorption
due to prolonged lifespan of osteo-
clasts on the other. In addition, cal-
cium/phosphate metabolism may be
disturbed through GC eﬀects on gut,
kidney, parathyroid glands and go-
nads. Therefore, therapeutic agents
aim at restoring balanced bone cell
activity by directly decreasing
apoptosis rate of osteoblasts (e.g.,
cyclical parathyroid hormone) or by
increasing apoptosis rate of osteo-
clasts (e.g., bisphosphonates). Other
therapeutical eﬀorts aim at main-
taining/restoring calcium/phosphate
homeostasis: improving intestinal
calcium absorption (using calcium
supplementation, vitamin D and
derivates) and avoiding increased
urinary calcium loss (using thiazides)
prevent or counteract a secondary
hyperparathyroidism. Bisphospho-
nates, particularly the ami-
nobisphosphonates risedronate and
alendronate, have been shown to
protect patients on GCs from
(further) bone loss and to reduce
vertebral fracture risk. Calcitonin
may be of interest in situations
where bisphosphonates are contra-
indicated or not applicable and in
cases where acute pain due to ver-
tebral fracture has to be managed.
The intermittent administration of
1-34-parathormone may be an
appealing treatment alternative,
based on its documented anabolic
eﬀects on bone resulting from the
reduction of osteoblastic apoptosis.
Calcium and vitamin D should be a
systematic adjunctive measure to
any drug treatment for GIOP. Based
on currently available evidence,
ﬂuoride, androgens, estrogens (op-
posed or unopposed) cannot be rec-
ommended for the prevention and
treatment of GIOP. However, sub-
stitution of gonadal hormones may
be indicated if GC-induced hypo-
gonadism is present and leads to
clinical symptoms. Data using the
SERM raloxifene to treat or prevent
GIOP are lacking, as are data using
the promising bone anabolic agent
strontium ranelate. Kyphoplasty
performed in appropriately selected
osteoporotic patients with painful
vertebral fractures is a promising
addition to current medical
treatment.
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Introduction
Glucocorticosteroid-induced osteoporosis (GIOP) is the
most common type of iatrogenic osteoporosis and also
the most frequent of all secondary types of osteoporosis
[21, 140]. The side eﬀects on bone are the most pre-
dictable and debilitating complication of prolonged
administration of systemic corticosteroids. Nevertheless,
for many clinical situations there are only limited alter-
natives to long-term use of glucocorticosteroids (GCs).
The thorough understanding of the underlying mecha-
nisms leading to GIOP serves as the basis for developing
and applying preventive and therapeutic treatment
strategies. The aim of this review is to highlight the most
recent ﬁndings regarding the pathophysiology of
GC-induced bone loss and to document their role
with regard to the development and implementation of
current or future treatment options.
Pathogenesis of glucocorticoid-induced osteoporosis
In GIOP, bone loss and the later development of osteo-
porosis with its well-known crippling consequences of
disability and fractures, result from several intricate and
interacting mechanisms (Fig. 1).
GCs depress bone formation by inhibiting osteo-
blastogenesis and increasing osteoblast apoptosis [89,
146]. Furthermore, GCs induce the in situ death of
isolated segments of bone (osteonecrosis), possibly in
relation to an increased osteocyte apoptosis [89, 146]
suggesting that GC-induced bone loss may arise from a
numerical decrease in bone cells. In addition, GCs may
further exacerbate the numerical decrease in osteoblasts
by altering the diﬀerentiation of stromal cells towards
the production of adipocytes rather than osteoblasts, an
eﬀect which may be related to the suppression of bone
morphogenic protein (BMP)-2 by GCs [90, 91]. Fur-
thermore GCs increase the expression of Notch1 and 2
in osteoblasts, a family of receptors considered to play a
negative role in osteoblastic cell diﬀerentiation [92], and
may suppress IGF-1 secretion and thereby inhibit
important stimulatory eﬀects on bone protein synthesis
[27, 79]. Finally, GCs induce modiﬁcations of the func-
tional characteristics of osteoblasts [76] by directly
suppressing their activity and thereby bone matrix syn-
thesis [18, 104].
In the early phase of GC treatment, bone resorption
is increased, a recent ﬁnding which has been associated
with a prolongation of the lifespan of osteoclasts, med-
iated by a GC-stimulated expression of RANK-ligand
[76, 77, 145, 147]. In vitro and animal models have
shown that GCs prolong the baseline survival of osteo-
clasts and antagonize their apoptosis by a glucocorticoid
receptor-mediated action [147].
Furthermore, GCs induce a dose-dependent inhibi-
tion of calcium (and possibly phosphate) absorption in
the gut and a compensatory increase in parathormone
secretion [35, 47], an increase in renal calcium elimina-
tion [17, 106], a reduction of the sex hormone levels
through inhibition of gonadotropin secretion [122] and
they directly interfere with estrogen, testosterone and
adrenal androgen production [25, 75].
Although the endocrine eﬀects on bone of GC ther-
apy contribute to or may even accelerate the develop-
ment of GIOP, the core pathogenetic processes aﬀect the
bone eﬀector cells. Many of the eﬀects of chronic GC
administration on bone can be explained by decreased
birth of osteoblast and osteoclast precursors and
increased apoptosis of mature osteoblasts and osteocytes,
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Fig. 1 Pathophysiology of
glucocorticosteroid-induced
osteoporosis. Glucocortico-
steroids exert direct deleterious
eﬀects on bone leading to
decreased formation and in-
creased resorption. In addition,
bone loss may be indirectly
promoted by reduced gonadal
hormone levels and by myopa-
thy as well as by decreased
calcium absorption from the
gut and increased renal calcium
excretion. However, secondary
hyperparathyroidism is an
inconstant ﬁnding
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disrupting the ﬁne balance between these processes. It is
therefore expected that therapeutic agents that alter the
prevalence of apoptosis of osteoblasts and osteoclasts
should be able to correct the imbalance in cell numbers
that is the basis of the diminished bone mass and
increased risk of fractures found in glucocorticoid-
induced osteoporosis [144].
Characteristics of GC-induced bone loss
Long-term administration of GCs induces a rapid loss of
bone mass of between 5 and 15% annually [36, 105].
Histomorphometric [70] as well as densitometric [126]
studies have shown that GC-induced bone loss is most
pronounced during the ﬁrst 3–12 months of therapy, but
continues as long as treatment is maintained.
The demineralization is more pronounced in trabec-
ular than in cortical bone compartments [4, 45, 128] and
not all regions of the skeleton are aﬀected alike. In a
study by Sambrook et al. [126], after 20 weeks of
treatment with prednisone (mean daily dose of 7.5 mg)
the average loss of bone density in the lumbar spine was
8% in heart transplant patients. In a longitudinal his-
tomorphometric study of LoCascio et al. [69], the
treatment with prednisone (10–25 mg) over 5–7 months
resulted in a reduction of 27% of the trabecular bone
volume in the crista iliaca.
Not all patients treated with GCs are similarly
aﬀected [105]. Diﬀerences are possibly genetically
determined and could be related to variants of the
steroid receptor and individual pharmacokinetic diﬀer-
ences. For example, it has been shown that the reductase
activity of 11 beta-hydroxysteroid dehydrogenase 1,
which converts inactive cortisone to active cortisol, is
increased in elderly subjects, which could explain the
susceptibility of these patients to the debilitating eﬀects
of GCs [22]. In addition, the synthesis and activity of
this enzyme are GC dependent so that administration of
GCs could possibly amplify their own eﬀectiveness [22].
The response of bone formation markers to GCs can be
predicted by the urinary measure of this enzyme, a
recent ﬁnding which may contribute to the identiﬁcation
of individuals at highest risk of developing GIOP [23].
Total bone mineral loss correlates directly with the
cumulatively given steroid dose [148]. Although 7.5 mg
of prednisone equivalent a day was considered to be the
threshold dose for skeletal side eﬀects [123, 124], recently
published data have shown that lower doses and even
inhaled GCs may induce skeletal side eﬀects [68]. In
children under low-dose inhaled steroids even impaired
growth has been demonstrated [68, 98]. In adults under
high-dose inhaled GCs, a dose-dependent reduction of
bone density has been observed [54], and the cumulative
dose of inhaled corticosteroids in adult asthmatics was
shown to correlate negatively with bone density [149].
Biochemical markers of bone formation and resorption
also were signiﬁcantly suppressed under inhaled corti-
costeroids, even with a short duration of treatment [84].
Giving GCs every second day, or using pulse therapy,
seems to have a favourable eﬀect on growth and on the
suppression of the hypothalamus–hypophysis–suprare-
nal axis but without eliminating entirely the unwanted
skeletal side eﬀects [40, 120]. Considering the dose
dependence of skeletal side eﬀects of systemic and
inhaled corticosteroids, the lowest eﬀective dose should
be used.
There are only marginal diﬀerences in the extent of
bone mineral loss between the diﬀerent types of corti-
costeroids. An exception may be the oxazolin derivative
deﬂazacort. Several trials have demonstrated that this
synthetic steroid has fewer side eﬀects on bone and
mineral metabolism compared to prednisone [35, 67, 70,
81]. However, these studies were based on an assump-
tion that the potency of prednisone relative to deﬂaza-
cort was 1.2. Recently published studies suggest that the
potency of deﬂazacort has been overestimated in the
past. Using a relative potency of 1.4–1.8 there may be no
bone-sparing eﬀect of this agent [61].
Bone loss induced by corticosteroid therapy is only
partly reversible, as observations after successful treat-
ment of Cushing’s disease [97] or after discontinuing
corticosteroid treatment [48, 117] show.
Although not all patients treated with GCs develop
GIOP and not all patients with GIOP experience frac-
tures, bone loss remains the most predictable, the most
frequent and potentially the most severe complication of
GC treatment. The appropriateness of bone protective
measures should be evaluated in all patients treated with
GCs or in whom such a therapy will be initiated.
Glucocorticosteroid treatment and fractures
Fracture risk increases in a dose-dependent manner in
patients treated with oral GCs [71]. In a prospective
study of asthmatics under long-term treatment with oral
corticosteroids (average duration of therapy 8 years),
the cumulative fracture incidence amounted to 40% [4],
while other authors reported a fracture incidence as high
as 50% [72, 83]. In a large retrospective cohort study,
oral treatment with GCs over a mean period of 1.3 years
signiﬁcantly increased the risk of non-vertebral and
vertebral fractures by 1.3 and 2.6, respectively. At doses
higher than 7.5 mg prednisone or equivalent during an
average 0.7 years, the risk for hip and vertebral fractures
was increased by 2.3 and 5.2, respectively, while this
increase was lower but still signiﬁcant for lower doses of
prednisone (<2.5 mg/day or equivalent) over a mean of
2.8 years, with relative risk (RR) increases for hip and
vertebral fractures of 1.2 and 1.6, respectively [137].
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These results suggested that the adverse skeletal eﬀects
of GCs increased with increasing daily doses [138]. In
addition, fracture risk was shown to increase rapidly
within the ﬁrst 3–6 months after initiation of therapy
with GCs and to remain increased during the whole
duration of treatment [140].
In patients with chronic obstructive pulmonary dis-
ease (COPD) treated with inhaled GCs for median
2.7 years, an increase in hip fracture risk was shown in a
large population based case-control study [53]. How-
ever, COPD is in itself a potential confounding factor
associated with an increased risk of osteoporosis due to
a variety of disease-related factors, such as poor health,
poor nutrition and tobacco consumption [139]. In con-
trast, a recent systematic review concluded that con-
ventional doses of inhaled GCs for 2–3 years did not
increase the risk of vertebral fractures [56]. However, the
patients included in the selected trials were at low risk
for osteoporosis and were not treated with high doses of
inhaled GCs.
In GIOP, vertebral body fractures may occur at
higher bone density values than usually observed in post-
menopausal osteoporosis [71, 141]. This observation may
be at least in part explained by an excessive and rapid
thinning of the trabeculae induced by GCs [132], which
leads to lower bone strength at identical bone mineral
density (BMD) values when compared to post-meno-
pausal osteoporosis. The BMD threshold for the
diagnosis of GIOP is therefore generally higher than the
T-score threshold of )2.5 standard deviations usually
accepted for primary osteoporosis and has been set at
)1.0 SD by the American College of Rheumatology [5],
while other countries and societies have chosen higher
thresholds [32] and/or approaches based on clinical risk
[38, 87, 142].
Although the underlying disease, which is the reason
for the prescription of GCs, may in itself bear charac-
teristics promoting the development of osteoporosis, GC
therapy is an ampliﬁer of the deleterious eﬀects on bone
and leads to increased fracture risk.
Treatment of GIOP
Any patient treated with GCs or in whom treatment
with GCs will be initiated should be assessed for the
presence of modiﬁable risk factors of osteoporosis, such
as alcohol intake, smoking, insuﬃcient physical activity,
low dietary calcium intake, and all eﬀorts should be
undertaken to correct or eliminate these risk factors. In
addition risk factors for fractures and falls, such as
advanced age, orthostatic hypotension, treatment with
hypnotic drugs, should be identiﬁed and appropriately
managed. Any other causes of secondary osteoporosis
such as hypogonadism, hyperparathyroidism or thyro-
toxicosis may potentiate the eﬀects of GCs on bone and
contribute to an even more rapid bone loss after the
initiation of treatment with GCs (Tables 1, 2, 3).
Based on the pathophysiology of GIOP, several
treatment approaches have been proposed to slow down
or stop bone loss and decrease subsequent fracture risk.
Current treatment options aim at restoring calcium
balance and countering secondary hyperparathyroidism
(calcium supplementation, vitamin D and derivates,
thiazides), at inhibiting bone resorption (bisphospho-
nates, calcitonin, estrogens), at improving bone forma-
tion (ﬂuoride, parathormone) or at exerting anabolic
eﬀects on bone (parathormone, androgens).
Calcium, vitamin D and thiazide diuretics
Glucocorticoid treatment results in decreased calcium
absorption in the gut and increased urinary calcium
elimination leading to a secondary increase in parat-
hormone. Interventions aiming at restoring calcium
Table 1 Pathophysiological rationale for use in the prevention and/or treatment of GIOP
Therapeutic agents Rationale for use in GIOP Proposed mechanism of action
Calcium, vitamin D and analogues Decreased calcium absorption in the gut Counter GC-induced secondary
hyperparathyroidism
Increased urinary elimination of calcium
Bisphosphonates Increased lifespan of osteoclasts Speciﬁc inhibition of bone resorption
Decreased lifespan of
osteoblasts and osteocytes
Reverse the increased osteoblast
and osteocyte apoptosis
Calcitonin Early increase in bone resorption Speciﬁc inhibitor of
osteoclast function
Parathormone (intermittent teriparatide) Increased osteoblast apoptosis Increases the lifespan of osteoblasts
Fluoride Increased osteoblast apoptosis Potent osteoblast mitogen
Androgens/estrogens (opposed or unopposed) Decreased sex hormone levels through
inhibition of gonadotropin
secretion and impairment of
androgen production
Increase levels of circulating
testosterone/estrogen
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balance and at countering secondary hyperparathy-
roidism have therefore been used as an empiric therapy
for osteoporosis of various aetiologies for several de-
cades. Calcium and vitamin D supplementation may
contribute to increased intestinal calcium absorption
and counter the mild secondary hyperparathyroidism
resulting from GC induced decreased calcium intestinal
absorption and increased calcium renal excretion [46].
Several authors have investigated their eﬀects on nega-
tive calcium balance occurring under corticosteroid
therapy [9, 46, 134].
In a recent meta-analysis, the eﬃcacy of active vita-
min D3 analogues in preserving bone and in decreasing
the risk of vertebral fractures was shown to be signiﬁ-
cantly higher than no treatment, placebo and plain
vitamin D3 with or without concomitant calcium [28].
Based on changes in lumbar spine BMD, calcitriol
(mean dose 0.6 lg/day), with and without calcium, was
signiﬁcantly more eﬃcacious than calcium in preventing
bone loss ()0.2 and )1.3% per year vs. )4.3% per year,
P=0.0035) but had no eﬀect at other clinically impor-
tant sites such as femoral neck and distal radius. Similar
results were reported by other authors [125] and with
other active vitamin D metabolites such as alfacalcidol
[13, 101, 112, 113].
The variability of the outcomes in published clinical
studies to date makes it diﬃcult to draw conclusions
concerning recommendations for the use of vitamin D
and its metabolites in patients under GC treatment,
though recent data suggest that active analogues of
vitamin D combined with calcium supplements are
helpful and cost eﬀective [14]. Calcium or vitamin D
alone or in combination has not been proven to stop or
prevent GC-induced bone loss and even less so to pre-
vent GIOP-related fractures in prospective randomized
trials. In the absence of contraindications, they should
however be considered as a mandatory supplementation
to the diet and as a systematic adjunctive measure to any
drug treatment against GIOP, whether the patient has
calcium and/or vitamin D deﬁciency or not.
In patients treated with GCs, hydrochlorothiazide
(25 mg b.i.d.) in combination with sodium restriction
was shown to increase intestinal calcium absorption and
to lower renal calcium excretion and thus to lower PTH
levels [111, 134]. However, the combination with vitamin
D may lead to increased risk of hypercalcaemia and to
worsening of the GC-induced hypokaliemia. While the
eﬀects of thiazide diuretics on bone are poorly docu-
mented in clinical trials, they may be considered based
on their mechanism of action for patients treated with
GCs who need additional antihypertensive treatment
[111].
Table 2 Treatment eﬀects of bone active substances in GIOP
Therapeutic agents Eﬀect on
BMD
Fracture risk in
GIOP patients
LS Hip Vertebral Non-vertebral
Calcium, vitamin D
and analogues
0 ) ? ?
Bisphosphonates
(alendronate, risedronate)
+ + ) ?
Calcitonin 0 ) ? ?
Parathormone
(intermittent teriparatide)
+ ? ? ?
Fluoride + 0/) + ? +
Androgens + ? ? ?
Estrogens
(opposed or unopposed)
+ ) ? ?
+ increase, 0 maintained, ) decreased, ? unknown,
LS lumbar spine
Table 3 Recommendation for
use in the prevention and
treatment of GIOP by
therapeutic class
Therapeutic agents Recommendation for use in GIOP
Calcium, vitamin D and
analogues
Systematic adjunctive measure to any drug treatment, whether
dietary intake is suﬃcient or not
Bisphosphonates (alendronate,
risedronate)
Gold standard, ﬁrst line choice
Calcitonin If bisphosphonates are contraindicated or for acute pain
management of vertebral fracture
Parathormone (intermittent
teriparatide)
Data expected, no recommendation possible at this stage
Fluoride No (increased risk for non-vertebral fractures)
Androgens No (paucity of data)
Estrogens (opposed or
unopposed)
No (paucity of data, trade-oﬀ between risks and beneﬁts)
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Bisphosphonates
Glucocorticoid treatment is associated with an increased
lifespan of the osteoclasts and a decreased lifespan of
osteoblasts and osteocytes. Bisphosphonates are speciﬁc
inhibitors of osteoclast-mediated bone resorption and
have been shown in vitro to reverse the increase in
osteocyte and osteoblast apoptosis caused by glucocor-
ticoids [96]. Bisphosphonates are the best documented
therapeutic class for the prevention [1, 12, 20, 29, 34, 41,
85, 119] and the treatment [2, 16, 37, 51, 95, 107, 110,
121] of GIOP and have shown consistent eﬃcacy in
preserving bone mass and/or in preventing fractures in
very heterogeneous patient populations of both genders,
for variable durations and dosages of GC treatment, for
various underlying diseases as reasons for the prescrip-
tion of GCs and across the individual compounds.
Cyclical administration of etidronate prevents bone
loss caused by GC treatment. In post-menopausal
women with newly started GC therapy, etidronate given
for 2 weeks every 3 months increased lumbar spine
BMD over 1 year by 1.4% while a decrease of 5% was
shown in the control group treated with calcium alone
[85]. In another study in post-menopausal women, the
cyclic administration of etidronate in combination with
the vitamin D metabolite ergocalciferol increased lum-
bar spine and femoral neck BMD by 7 and 2.5%
respectively, in the ﬁrst year of GC therapy, while in the
second year BMD continued to increase at the femoral
neck and remained stable at lumbar spine [29]. Fur-
thermore, in a randomized placebo-controlled trial, 141
men and women recently started on GC therapy were
treated for 1 year with either etidronate (400 mg/day) or
placebo for 14 days, followed by calcium (500 mg/day)
for 76 days: with etidronate bone density increased
signiﬁcantly at lumbar spine and trochanter, but not at
the femoral neck [1]. Similar results were reported in
another study with 117 patients followed over 1 year
[119]. Cyclical etidronate has also been documented for
the treatment of GIOP. In a 2-year study in patients
treated with GCs for at least 6 months and with low
BMD, lumbar spine BMD signiﬁcantly increased after
6 months of treatment with etidronate and remained
stable for the remaining 18 months [95]. These results
were conﬁrmed by another study in post-menopausal
women with low BMD taking GCs for at least 3 months
[37]. In a recently published study over 5 years, includ-
ing 352 patients who had been taking GCs for at least
1 year for the treatment of asthma, cyclical etidronate
caused a signiﬁcant increase in lumbar spine BMD [16].
Although the results on BMD were consistent across
studies, reduction of fracture risk could not be estab-
lished with etidronate [1, 16].
Intravenous cyclical pamidronate in combination
with a calcium supplement was shown to protect
patients beginning GC therapy from GC-induced bone
loss [11, 12] and to increase BMD in patients with low
bone mass treated with GCs [107].
High-dose oral clodronate (2,400 mg/day) was shown
to increase BMD at lumbar spine, femoral neck and
trochanter in patients on long-term GC therapy for
asthma over 12 months of treatment [51]. Intramuscular
clodronate (100 mg) administered once weekly to
patients with rheumatoid arthritis treated with GCs
prevented BMD loss at the lumbar spine, the hip and
total body while the patients treated with placebo
experienced a continuous loss in bone mass over 4 years.
The diﬀerence between the two groups was already
signiﬁcant after 12 months of treatment and a signiﬁcant
reduction in the incidence of vertebral fractures could be
shown [34].
The eﬀects of alendronate in preventing GIOP were
ﬁrst published in 1997 in a study in 30 patients starting
GC therapy for sarcoidosis [41]. Half of the patients
received a placebo and half alendronate (5 mg/day). A
third group of patients required no GC treatment and
served as a control group. In untreated patients BMD
remained stable over the duration of the study ()0.6%),
while BMD signiﬁcantly decreased by 4.5% in the pla-
cebo group. Alendronate prevented the loss in BMD
observed with GCs and increased BMD by 1.0% at
6 months and 0.8% after 1 year. These results were
conﬁrmed in a large, multicentre study in which all
patients received at least 7.5 mg prednisone/day or its
equivalent and in addition a placebo, 2.5, 5 or 10 mg
alendronate/day [121]. After 48 weeks, BMD was sig-
niﬁcantly increased in the lumbar spine, trochanter and
femoral neck in the groups receiving 5 or 10 mg
alendronate/day, irrespective of the dose or previous
duration of GC therapy. These results were conﬁrmed in
the 12-month extension that included 208 of the initially
enrolled patients. During this extension the incidence of
new vertebral fractures was signiﬁcantly reduced with
alendronate versus placebo (6.8% placebo vs. 0.7%
pooled alendronate, P<0.05) [2].
The therapeutic eﬀects of risedronate have been
examined in two multicenter, randomized, double-
blind, placebo-controlled, parallel-group studies of
similar design including men and women all receiving
calcium supplementation of 500–1,000 mg and most
receiving vitamin D supplementation 400 IU daily: a
prevention study (n=228) with patients treated for less
than 3 months with GCs [20] and a treatment study
(n=290) with patients treated with high-dose (predni-
sone ‡7.5 mg/day or equivalent) oral GCs for at least
6 months prior to enrolment [109]. In the prevention
study, lumbar spine BMD was preserved versus base-
line in both risedronate (2.5 or 5 mg/day) treatment
groups. BMD values at the lumbar spine, the femoral
neck and the trochanter were signiﬁcantly increased
versus placebo in the risedronate 5 mg daily treatment
group (+3.8±0.8, +4.1±1.0 and +4.6±0.8%,
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respectively, P<0.001 for all) while no signiﬁcant dif-
ferences were observed in the risedronate 2.5 mg daily
treatment group or in either group at the radius. A
trend toward a decrease in the incidence of vertebral
fractures was observed in the 5 mg risedronate group
compared with the placebo group (5.7 vs. 17.3%;
P=0.072) [20]. In the treatment study, risedronate
5 mg daily signiﬁcantly increased BMD by an average
of 2.9% at the lumbar spine, 1.8% at the femoral neck
and 2.4% at the trochanter (P<0.05 for all), whereas
BMD was only maintained in the control group. The
incidence of vertebral fractures was reduced by 70% in
the combined risedronate treatment groups versus
placebo (P=0.042). These results were conﬁrmed in the
pooled analysis (n=518) of these two studies of similar
design [143]. Altogether osteoporosis was present in
35%, osteopenia in 44% and a normal bone density in
21% of the patients. The percentage of patients with pre-
existing spinal fractures was 34% (placebo), 28%
(risedronate 2.5 mg/day) and 35% (risedronate 5 mg/
day). The overall vertebral fracture risk reduction with
risedronate 5 mgdailywas 70%versus placebo (P=0.01).
Therefore, the bisphosphonates have demonstrated
their ability to protect patients treated with GCs from
(further) bone loss at all clinically relevant sites inclu-
ding the hip, and have proven their eﬃcacy in reducing
fracture risk in the axial skeleton. Based on the hetero-
geneity of patients included in the diﬀerent studies, these
results may be generalized to the patient population seen
in daily medical practice [19].
Calcitonin
Calcitonin inhibits bone resorption through speciﬁc
receptors located on the osteoclasts and bone resorption
is increased under GC therapy, at least during the early
phase of treatment.
In a recent systematic review of nine randomized
controlled trials in GIOP [24] including 221 patients
randomized to calcitonin and 220 to placebo, calcitonin
was shown to be more eﬀective than placebo at pre-
serving bone mass at the lumbar spine after 6 and
12 months of therapy, but not at the femoral neck.
There was no consistent eﬀect of diﬀerent dosages (50–
100 IU compared to 200–400 IU) on spinal BMD,
although the subcutaneous administration route showed
a substantially greater eﬀect than the intranasal route.
With a relative risk (RR) of 0.71 (95% CI: 0.26–1.89) for
vertebral and 0.52 (95% CI: 0.14–1.96) for non-vertebral
fractures, the risk of fractures was not signiﬁcantly dif-
ferent between calcitonin and placebo. In patients with
steroid-dependent, chronic obstructive lung disease and
associated steroid-induced osteoporosis, calcitonin was
shown to reduce back pain signiﬁcantly versus untreated
controls [115, 116].
As calcitonin may preserve spinal but not femoral
neck BMD in the ﬁrst year of GC therapy and as its
eﬃcacy for fracture prevention in steroid-induced osteo-
porosis remains to be established [24], bisphosphonates
should be preferred for the treatment and the prevention
of GIOP. Calcitonin may be of interest in those patients
where bisphosphonates are contraindicated or not
applicable and to manage acute pain due to vertebral
fracture.
Parathormone
Glucocorticoid therapy induces a secondary hyper-
parathyroidism as a response to negative calcium bal-
ance, and the continuous administration of synthetic
human parathyroid hormone 1–34 has been shown to
lead to a high bone turnover status in which bone
resorption exceeds the capacity of bone formation,
resulting in increased cortical porosity and increased
bone fragility [136]. The administration of parathor-
mone (PTH) to treat or prevent GIOP may therefore
appear to be paradoxical at ﬁrst sight.
While a sustained elevation of PTH was shown to
stimulate bone resorption, an intermittent administra-
tion stimulated bone formation [8, 55]. In mice, inter-
mittent administration of PTH increased the lifespan of
mature osteoblasts thereby increasing osteoblast num-
ber, bone formation rate and bone mass, but did not
aﬀect osteoclasts. In contrast, sustained elevation of
PTH did not aﬀect osteoblast apoptosis but increased
osteoclast number [8, 55]. Therefore, the antiapoptotic
eﬀect of PTH on osteoblasts is an appealing therapeutic
concept in GC-induced osteoporosis, and may be con-
sidered as a causal counter measure against the delete-
rious eﬀects of GCs on the osteoblasts [55].
The intermittent administration of PTH 1–34 leads to
increased bone formation, with increased trabecular
bone volume without loss of cortical bone volume [136].
Thus, intermittent and continuous PTH increase bone
formation independently of eﬀects on bone resorption,
but only intermittent PTH increases bone mass
consistently [52]. Such an intermittent administration of
PTH 1–34 was shown to have a marked anabolic eﬀect
on the skeleton in patients on hormone replacement
therapy (HRT), associated with a reduced incidence of
vertebral fractures, despite increased bone turnover [65].
These early ﬁndings were conﬁrmed by a prospective
randomized placebo-controlled fracture endpoint study
in 1,637 post-menopausal women with prior vertebral
fractures who received a daily subcutaneous dose of
recombinant human PTH 1–34 (teriparatide). The risk
for new vertebral fractures was signiﬁcantly reduced by
up to 69%, while the risk of new non-vertebral fragility
fractures was signiﬁcantly reduced by up to 54% versus
placebo. BMD was increased at lumbar spine and
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femoral neck but not at the radius [88]. This increase in
BMD corresponds to an increase in bone formation
known to occur on trabecular, endocortical and perio-
steal surfaces with intermittent daily teriparatide treat-
ment. Consistently, an increase in vertebral size has
been described in 51 post-menopausal women treated
chronically with both glucocorticoids and HRT and
randomized to either intermittent PTH 1–34 or placebo
for 12 months. Since vertebral fracture risk is related to
both bone size and bone mass, this increase in vertebral
size has been proposed as part of the explanation of the
fracture risk reduction associated with this therapy [103].
In estrogen replete post-menopausal osteoporotic
women treated with glucocorticoids for inﬂammatory
diseases, bone formation (bone speciﬁc alkaline phos-
phatase and osteocalcin) and bone resorption markers
(deoxypyridinoline) were signiﬁcantly increased as a
result of PTH treatment over 24 months (P<0.01 vs.
placebo) while the change in resorption lagged behind
the increase in formation [62, 63].
Although patients treated with GCs may develop an
infraclinical secondary hyperparathyroidism as a com-
pensatory mechanism of their relative hypocalcaemia,
the intermittent administration of parathormone may be
a conceptually appealing treatment alternative for
patients with GIOP, based on its documented anabolic
eﬀects on bone resulting from the reduction of osteo-
blastic apoptosis. However, the evidence of fracture risk
reduction in patients treated with GCs is still lacking.
Fluoride
Increased osteoblast apoptosis and resulting decreased
osteoblast cell number is one of the key features in the
development of GIOP. This observation triggered the
idea of trying to stimulate bone formation directly with
ﬂuoride, a potent osteoblast mitogen.
Although initial results with natrium ﬂuoride and
disodium monoﬂuorophosphate looked promising from
the BMD increases reported at the lumbar spine [43, 64,
66, 82, 114], early concerns were unveiled/revealed at the
femoral neck level, where at best no eﬀect was observed
[64, 66, 114], triggering the question of the antifracture
eﬃcacy of ﬂuoride in patients with GIOP. A recent
meta-analysis based on a systematic review of the liter-
ature [44] including 11 studies with 1,429 post-meno-
pausal women enrolled concluded that although ﬂuoride
had an ability to increase BMD at the lumbar spine, it
did not result in a reduction in vertebral fractures. In
addition, increasing the dose of ﬂuoride increased the
risk of non-vertebral fractures and gastrointestinal side-
eﬀects without any eﬀect on the vertebral fracture rate.
The RR for new vertebral fractures was not signiﬁcantly
reduced at 2 years [0.87 (95% CI: 0.51–1.46)] or at
4 years [0.9 (95% CI: 0.71–1.14)], nor was there a
decrease in the RR for non-vertebral fractures at 2 years
[1.2 (95% CI: 0.68–2.10)]. On the contrary, the latter was
signiﬁcantly increased at 4 years [1.85 (95% CI: 1.36–
2.50)], especially for those patients using high dose and
non-slow-release ﬂuoride formulations [44]. Thus, the
increase in bone density under ﬂuoride therapy is not
accompanied by a corresponding decrease in the inci-
dence of vertebral or non-vertebral fractures and even
the opposite may apply.
While ongoing research may reﬁne the narrow thera-
peutic window for the safe and eﬀective use of ﬂuoride,
and although the results reported qualify for post-meno-
pausal women and not necessarily for GIOP, prudent
prescription should be recommended—particularly since
other treatment and prevention alternatives for GIOP,
such as the bisphosphonates have demonstrated their
safety and eﬃcacy in clinical trials and daily practice.
Gonadal hormone substitution: androgens, estrogens
and progestins
GC therapy is known to decrease sex hormone levels
through inhibition of gonadotropin secretion and direct
impairment of estrogen and androgen production.
Circulating testosterone concentrations are reduced
in men treated with glucocorticoids, which might con-
tribute to the loss of bone mass, and low circulating
levels of free testosterone in post-menopausal women
have been associated with an increased risk for hip and
vertebral fractures [26]. Natural and synthetic andro-
gens have been shown to have anabolic eﬀects on bone
[127].
In asthmatic men receiving long-term GC treatment,
testosterone treatment was shown to increase lumbar
spine BMD by 5.0% over 12 months [108]. In women
treated with GCs for rheumatic disease, nandrolone
decanoate signiﬁcantly increased forearm bone density
by 5.1% over 18 months versus baseline (P<0.01) [3].
However, due to the paucity of published data andro-
gens cannot be recommended for routine use to prevent
or treat GIOP.
Estrogens have been shown to inhibit osteoclastic
bone resorption, and in post-menopausal women, lower
circulating levels of circulating estradiol have been
associated with an increased risk of vertebral and non-
vertebral fractures [26]. In addition, HRT has been
shown to reduce signiﬁcantly the risk of hip, vertebral
and other osteoporotic fractures in post-menopausal
women [118]. On the other hand, progesterone binds
competitively to the GC receptor of the osteoblast and
may act as a GC antagonist [99, 135]. However, pub-
lished randomized controlled trials of HRT in the pre-
vention or treatment of GIOP are rare.
In a retrospective study of 15 post-menopausal or
amenorrheic women aged 34–78 years under long-term
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high-dose GC treatment, HRT was shown to increase
signiﬁcantly lumbar spine BMD, while the untreated
controls were continuously losing bone mass over
12 months [73]. In 200 post-menopausal women with
rheumatoid arthritis and 21% of them treated with GC,
BMD increased signiﬁcantly at the lumbar spine with
HRT versus calcium 500 mg daily with no signiﬁcant
diﬀerence at the femoral neck [49]. The administration
of a long-acting progestin (17-alpha-hydroxy-proges-
terone-kaproat) in patients with steroid dependent
asthma led to a considerable increase of the vertebral
bone density (+17%), without unwanted side eﬀects on
the lipid proﬁle [42].
While HRT was shown to reduce signiﬁcantly the
fracture risk in post-menopausal women in an ade-
quately powered long-term prospective randomized
study, the same study documented an increased risk of
invasive breast cancer, coronary heart disease, stroke
and pulmonary embolism and concluded that in post-
menopausal women the overall health risks of HRT
exceeded the potential beneﬁts [118]. In post-meno-
pausal women with prior hysterectomy, conjugated
equine estrogen signiﬁcantly increased the risk of stroke
and decreased the risk of hip fracture over an average of
6.8 years, with an absolute excess risk of 12 additional
strokes and an absolute risk reduction of six fewer hip
fractures per 10,000 person-years [6]. Thus, HRT (op-
posed or unopposed estrogen substitution) should not be
recommended for the prevention of osteoporosis in post-
menopausal women. Whether a similar risk–beneﬁt ratio
would apply to women at increased risk for osteoporosis
and osteoporotic fracture due to GC therapy was not
established. However, based on currently available evi-
dence HRT cannot be recommended for routine pre-
vention or treatment of GIOP, and each prescription
supposes that the risks are weighed against the beneﬁts
and adequate patient information about and acceptance
of the trade-oﬀ has been given.
Tamoxifen, a partial estrogen agonist used as adju-
vant endocrine treatment in post-menopausal women
with operable breast cancer may inhibit bone resorption,
and it has been shown to protect from steroid-induced
bone loss over 2 years [33]. Raloxifene, a speciﬁc estro-
gen receptor modulator, lacks any published data for use
in GIOP.
Physical medicine and rehabilitation
Fractures are associated with signiﬁcant performance
impairments in physical, functional and psychosocial
domains in older women [74] and home exercise pro-
grams have not been shown to improve outcomes in
post-menopausal women at high risk of fracture [59, 60].
However, controlled trials have shown that musculo-
skeletal changes related to osteoporosis can be pre-
vented, challenged or reduced with the implementation
of adequate patient-tailored rehabilitation programs
[129]. The beneﬁts of exercise and physical medicine
measures have been reviewed extensively very recently
[7, 94] and conﬁrmed their importance in reducing the
risk of falls and fractures, in decreasing pain and in
improving ﬁtness and overall quality of life in patients
with osteoporosis [100]. In osteoporotic or high-risk
patients, immobilization should be avoided as much as
possible and a regular, albeit moderate physical activity
recommended for those with osteoporosis. Speciﬁc fall
prevention programs may contribute to improve neu-
romuscular coordination and thereby contribute to
reduce the risk and the consequences of falling [93, 133].
Younger people with osteoporosis also need exercise
that will preserve or improve bone mass, muscular
strength, endurance and cardiovascular ﬁtness [10]. Al-
though braces have neither been shown to lower BMD
in adolescents [130, 131] nor to impact back strength in
women with osteoporosis [57], conclusive studies are
lacking and immobilization is generally not recom-
mended. Physical medicine and rehabilitation measures
are independent contributors to bone health [100] and
should be systematically evaluated and proposed
together with dietary and drug therapy measures to
every patient suﬀering from or at risk for osteoporosis.
Vertebroplasty and surgery for spine deformity
The surgical treatment of spine deformities can be very
challenging due to the usually poor bone quality and to
the patient’s expectations regarding the improvement of
chronic pain, which need to be clariﬁed upfront [39]. For
the management of acute pain resulting from vertebral
fractures and based on recent clinical results, percuta-
neous vertebroplasty has become an interesting treat-
ment option to improve functionality and quality of life.
When compared with conservative therapy, percuta-
neous vertebroplasty results in prompt pain relief and
rapid rehabilitation and has become a safe and eﬀective
procedure for treating acute osteoporotic vertebral
compression fractures [30]. The reported improvements
are maintained for at least 6 months and there is no
apparent increase in the incidence of fractures post-
operatively [80]. In a recently published prospective
study including 60 patients with primary osteoporosis
and painful vertebral fractures, kyphoplasty was shown
to increase vertebral height signiﬁcantly, to reduce pain
and improve mobility [58].
Publications on the prospective clinical outcomes
(pain relief, consumption of narcotic analgesics) of ver-
tebroplasty in patients with acute vertebral compression
fractures as a complication of GIOP are limited to case
reports [31, 78]. However, in a retrospective review of
prospective databases including 225 vertebral bodies
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treated by kyphoplasty in 115 patients (80 with primary
osteoporosis and 35 with GIOP), the incidence of post-
kyphoplasty vertebral compression fractures was 11.3%
in the primary osteoporosis group and 48.6% in the
GIOP group (P<0.0001) over an average 11 months of
follow-up, suggesting that patients with steroid-induced
compression fractures may have an increased incidence
of subsequent fractures after a kyphoplasty procedure
[50].
Therefore, kyphoplasty performed in appropriately
selected osteoporotic patients with painful vertebral
fractures is a promising addition to current medical
treatment and more research is needed in patients with
GIOP in order to understand better the determinants of
fracture risk in this speciﬁc patient population.
Conclusions
Fractures are the most frequent and debilitating con-
sequence of GIOP. New insights into the pathophysi-
ology of GC-induced osteoporosis have greatly
contributed to the understanding of the mechanisms
behind the disease and to the development of innovative
preventive and therapeutic solutions. Among these, the
bisphosphonates risedronate and alendronate have
established themselves as the current gold standard for
the prevention and treatment of GIOP, based on their
documented increase in BMD at all clinically relevant
sites and their proven ability to reduce fractures.
Calcitonin may be an interesting alternative for
patients in whom bisphosphonates cannot be given
and/or who are suﬀering from acute pain after an
osteoporotic fracture. Parathormone is a conceptually
attractive and promising treatment alternative,
although data about fracture risk reduction are still
lacking for patients with GIOP.
Interestingly, the main challenge in the prevention
and treatment of GIOP may come from the medical
community itself, as the main hurdle to treat such a
severe disease remains the low awareness of the conse-
quences on bone of GC therapy and the related low
intervention rate [15]. Things are, however, evolving
rapidly as recent educational programmes have been
shown to double the prevalence of preventative therapy
for GIOP in hospital patients taking GCs [86].
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